Increased expression of SARS-CoV-2 (Covid-19) adhesion sites on type II pneumocytes, small airway epithelium, and alveolar macrophages in smokers and patients with COPD

S. Brake (Launceston (TAS), Australia), W. Lu (Launceston (TAS), Australia), J. Markos (Launceston (TAS), Australia), J. Larby (Launceston (TAS), Australia), C. Chia (Launceston (TAS), Australia), G. Haug (Launceston (TAS), Australia), H. Weber (Launceston (TAS), Australia), K. Mcalinden (Launceston (TAS), Australia), A. Hardikar (Launceston (TAS), Australia), G. Singhera (Launceston (TAS), Canada), T. Hackett (Launceston (TAS), Canada), M. Eapen (Launceston (TAS), Australia), S. Sohal (Launceston (TAS), Australia)

Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Session: Mechanistic pathways in chronic and new lung diseases
Session type: Oral Presentation
Number: 1217

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Brake (Launceston (TAS), Australia), W. Lu (Launceston (TAS), Australia), J. Markos (Launceston (TAS), Australia), J. Larby (Launceston (TAS), Australia), C. Chia (Launceston (TAS), Australia), G. Haug (Launceston (TAS), Australia), H. Weber (Launceston (TAS), Australia), K. Mcalinden (Launceston (TAS), Australia), A. Hardikar (Launceston (TAS), Australia), G. Singhera (Launceston (TAS), Canada), T. Hackett (Launceston (TAS), Canada), M. Eapen (Launceston (TAS), Australia), S. Sohal (Launceston (TAS), Australia). Increased expression of SARS-CoV-2 (Covid-19) adhesion sites on type II pneumocytes, small airway epithelium, and alveolar macrophages in smokers and patients with COPD. 1217

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects
Source: Eur Respir J, 56 (2) 2002378; 10.1183/13993003.02378-2020
Year: 2020



Hyperoxia reversibly inhibits the transdifferentiation of alveolar type II (ATII) cells to alveolar type I (ATI) cells
Source: Annual Congress 2005 - Cellular and molecular approaches to lung injury research
Year: 2005


Decreased expression of TGFβ1 type II receptor in bronchial glands of smokers with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 98s
Year: 2004

Chlamydia pneumoniae persists in TLR2 positive alveolar epithelial cells type II and alveolar macrophages of COPD patients
Source: Eur Respir J 2003; 22: Suppl. 45, 350s
Year: 2003

Modulation of NOS2 expression in co-cultures of human alveolar epithelial cells type II and alveolar macrophages
Source: Eur Respir J 2001; 18: Suppl. 33, 161s
Year: 2001

Expression of surface receptors on alveolar macrophages and monocytes from patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 453s
Year: 2004

Type I and III collagen protein precursors in the airways of smokers and COPD-patients
Source: Annual Congress 2008 - Structural remodelling in COPD
Year: 2008


Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD
Source: Eur Respir J 2007; 29: 914-922
Year: 2007



Reduced haemeoxygenase-1 immunoreactivity in alveolar macrophages in severe COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 75s
Year: 2001

PP207 – Targeting p16INK4a in alveolar type 2 cells to induce endogenous lung alveolar regeneration
Source: ERS Lung Science Conference 2021
Year: 2021

RAGE, a marker of alveolar epithelial type I cell injury, predicts impaired alveolar fluid clearance in isolated perfused human lungs
Source: Annual Congress 2007 - New insights into clinical lung transplantation
Year: 2007


Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD
Source: Eur Respir J 2002; 20: 556-563
Year: 2002



Antigen presenting cells of lower airways in interstitial lung diseases (ILD). Do alveolar lymphocytes possess the ability to present antigens?
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010

Expression of versican in large and small airways and parenchyma in lungs of non-smokers, smokers and COPD patients
Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury
Year: 2009


Effect of cigarette smoking on alveolar macrophages (AM) and lymphocytes (AL) apoptosis in selected interstitial lung diseases (ILD)
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008


Altered phenotype of COPD primary fibroblasts from airway and alveolar tissues: proliferation and apoptosis.
Source: International Congress 2019 – Research and innovation in airway diseases
Year: 2019

The relative expression of genes for arginine transporters in alveolar macrophages from BAL of non specific interstitial pneumonia patients (NSIP)
Source: Annual Congress 2007 - Invasive and noninvasive methods to assess airway inflammation
Year: 2007


ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19
Source: Eur Respir J, 55 (5) 2000688; 10.1183/13993003.00688-2020
Year: 2020



Decreased VEGF concentration in lung tissue and vascular injury during ARDS
Source: Eur Respir J 2005; 25: 139-146
Year: 2005



The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair
Source: Eur Respir J 2004; 24 : 664-673
Year: 2004